查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985863

心臟生物標記市場規模、佔有率和趨勢分析報告：按類型、應用、最終用途、地區和細分市場分類 - 預測，2026-2033 年

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, Creatine kinase - MB, Myoglobin, BNP and NT-proBNP), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

心臟生物標記市場概述

全球心臟生物標記市場預計到 2025 年價值 208.1 億美元，預計到 2033 年將達到 493.1 億美元，2026 年至 2033 年的複合年成長率為 11.5%。

心血管疾病（如急性冠狀動脈症候群、心肌梗塞和心臟衰竭）的日益普遍推動了這一市場的發展，導致對早期準確診斷的需求增加。

高敏肌鈣蛋白檢測和多標記檢測技術的進步改善了臨床決策和患者預後。此外，就地檢驗的日益普及、有利的報銷機制以及老年人口不斷成長（老年人患心臟病的風險較高）等因素，持續推動著全球市場的擴張。

心血管疾病是全球主要死因之一。根據世界衛生組織（WHO）2023年的調查，每年約有1,790萬人死於心臟病。老化、肥胖、糖尿病和高血壓等因素持續加劇這些疾病的盛行率，導致越來越多的人面臨心臟病發作和心臟衰竭的風險。隨著心血管疾病負擔的加重，早期發現、準確診斷和有效病患監測的需求變得特別迫切。心臟生物標記在此發揮至關重要的作用。肌鈣蛋白、肌酸激酶-MB（CK-MB）和肌紅蛋白等生物標記對於檢測心肌損傷和評估疾病嚴重程度至關重要，有助於指導治療決策。

對即時檢測（POC​​）心臟檢測套組日益成長的需求預計將進一步推動心臟生物標記市場的成長。傳統上，心血管疾病的診斷依賴中心檢查室的檢測，這需要專門的設備和訓練有素的人員。這些傳統系統可能導致診斷和治療的延誤，尤其是在急性情況下，例如疑似胸痛或心肌梗塞的急診就診。此類延誤可能造成嚴重的臨床後果，因為及時識別心臟事件對於啟動干預措施和提高患者存活率至關重要。即時檢測心臟檢測套組能夠在患者照護場所（例如急診室、循環系統診所和居家醫療機構）直接實現快速診斷結果和及時決策。肌鈣蛋白、腦鈉肽 (BNP) 和肌酸激酶-MB (CK-MB) 等關鍵生物標記現在可以在臨床環境中進行測量，使臨床醫生能夠更快地做出治療決策。例如，即時檢測肌鈣蛋白 (cTn) 通常在 10 到 20 分鐘內即可提供結果。

新型生物標記，例如可溶性腫瘤抑制因子-2 (sST2)、心臟脂肪酸結合蛋白質(H-FABP)、半乳糖凝集素-3 和生長分化因子-15 (GDF-15)，因其潛在的臨床效用而備受關注。例如，MDPI 於 2025 年 8 月發表的一項研究報告稱，GDF-15、sST2、suPAR 和 H-FABP 等生物標記在多種心血管疾病中顯示出良好的應用前景。

這些新型生物標記不僅反映了心血管生理的各個方面，而且有望改善早期診斷和治療反應監測。高靈敏度檢測和奈米技術感測器等技術的進步，進一步提高了在極低濃度下檢測這些生物標記的能力，從而能夠更快、更準確地做出臨床決策。此外，透過將多種生物標記組合成一個檢測組合，臨床醫生可以更全面地了解患者的心血管狀態，從而實現更個人化和精準的治療方案。隨著研究的深入和更多證據的出現，這些新型心臟生物標記有望在改善心臟病患者的預後方面發揮關鍵作用。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場歷史及展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
  • 商業環境分析
    • PESTLE分析
    • 波特五力分析
  • 新冠疫情影響分析

第4章 按類型進行業務分析

  • 心臟生物標記市場：按類型分類的波動分析，2025-2033年
  • 肌鈣蛋白
  • CK-MB
  • 肌紅蛋白
  • BNP,NT-proBNP
  • 其他

第5章 應用業務分析

  • 心臟生物標記市場：基於應用領域的波動分析，2025-2033年
  • 急性冠狀動脈症候群
  • 心肌梗塞
  • 鬱血性心臟衰竭
  • 其他

第6章 依最終用途進行業務分析

  • 心臟生物標記市場：以最終用途分類的波動分析，2025-2033年
  • 實驗室檢測
  • 即時檢測

第7章：按地區分類的業務分析

  • 區域市場概覽
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 獲得
    • 合夥
    • 新平台推出
    • 其他
  • 公司簡介/上市資訊
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers
    • Danaher
    • F. Hoffmann-La Roche Ltd
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd
    • Creative Diagnostics
    • Life Diagnostics
Product Code: GVR-1-68038-083-5

Cardiac Biomarkers Market Summary

The global cardiac biomarkers market size was estimated at USD 20.81 billion in 2025 and is expected to reach USD 49.31 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is driven by the rising prevalence of cardiovascular diseases such as acute coronary syndrome, myocardial infarction, and heart failure, increasing the demand for early and accurate diagnosis.

Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.

Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.

The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.

Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.

These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient's cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.

Global Cardiac Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the cardiac biomarkers market based on type, application, end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Troponin
  • CK-MB
  • Myoglobin
  • BNP and NT-proBNP
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Testing
  • Point of Care Testing
  • Regional Outlook (Revenue, USD Million, 2021-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Application and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing prevalence of cardiovascular diseases
      • 3.3.1.2. Rising demand for point of care (POC) cardiac testing kits
      • 3.3.1.3. Increasing focus on innovation and development of novel cardiac biomarkers
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Stringent regulatory barriers
      • 3.3.2.2. Lack of specificity in cardiac biomarkers
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Cardiac Biomarkers Market: Type Movement Analysis, 2025 & 2033
  • 4.2. Troponin
    • 4.2.1. Troponin market, 2021 - 2033 (USD Million)
  • 4.3. CK-MB
    • 4.3.1. CK-MB market, 2021 - 2033 (USD Million)
  • 4.4. Myoglobin
    • 4.4.1. Myoglobin market, 2021 - 2033 (USD Million)
  • 4.5. BNP and NT-proBNP
    • 4.5.1. BNP and NT-proBNP market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Cardiac Biomarkers Market: Application Movement Analysis, 2025 & 2033
  • 5.2. Acute Coronary Syndrome
    • 5.2.1. Acute coronary syndrome market, 2021 - 2033 (USD Million)
  • 5.3. Myocardial Infarction
    • 5.3.1. Myocardial infarction market, 2021 - 2033 (USD Million)
  • 5.4. Congestive Heart Failure
    • 5.4.1. Congestive heart failure market, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Cardiac Biomarkers Market: End Use Movement Analysis, 2025 & 2033
  • 6.2. Lab Testing
    • 6.2.1. Lab testing Market, 2021 - 2033 (USD Million)
  • 6.3. POC testing
    • 6.3.1. POC testing Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Germany Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Competitive Scenario
    • 7.3.3. UK
      • 7.3.3.1. UK Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Competitive Scenario
    • 7.3.4. France
      • 7.3.4.1. France Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Competitive Scenario
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Competitive Scenario
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Competitive Scenario
    • 7.4.6. Australia
      • 7.4.6.1. Australia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Competitive Scenario
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Key Country Dynamics
    • 7.5.3. Regulatory Framework
    • 7.5.4. Competitive Scenario
    • 7.5.5. Brazil
      • 7.5.5.1. Brazil Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.5.2. Key Country Dynamics
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Competitive Scenario
    • 7.5.6. Argentina
      • 7.5.6.1. Argentina Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.6.2. Key Country Dynamics
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Platform Launches
    • 8.2.4. Others
  • 8.3. Company Profiles/Listing
    • 8.3.1. Abbott
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Quidel Corporation
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Siemens Healthineers
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Danaher
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. bioMerieux SA
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Rad Laboratories, Inc.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Randox Laboratories Ltd
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Creative Diagnostics
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Life Diagnostics
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Global Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 3 Global Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 5 Global Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 7 North America Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 8 North America Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 9 North America Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 U.S Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 11 U.S Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 12 U.S Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 13 U.S Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 15 Canada Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 17 Canada Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 20 Mexico Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 21 Mexico Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Europe Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 23 Europe Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 24 Europe Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 25 Europe Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 27 UK Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 28 UK Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 29 UK Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 30 Germany Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 31 Germany Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Germany Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 33 Germany Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 34 France Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 35 France Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 36 France Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 37 France Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Italy Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 39 Italy Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 40 Italy Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 41 Italy Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 42 Spain Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 43 Spain Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 44 Spain Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 45 Spain Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 48 Denmark Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 49 Denmark Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 51 Sweden Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 52 Sweden Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 53 Sweden Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 55 Norway Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 56 Norway Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 57 Norway Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 Japan Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 63 Japan Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Japan Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 65 Japan Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 66 China Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 67 China Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 China Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 69 China Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 70 India Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 71 India Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 India Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 73 India Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 74 Australia Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 75 Australia Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 Australia Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 77 Australia Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 78 South Korea Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 79 South Korea Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 South Korea Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 81 South Korea Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Latin America Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 83 Latin America Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 Latin America Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 85 Latin America Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 86 Brazil Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 87 Brazil Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Brazil Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 89 Brazil Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 90 Argentina Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 91 Middle East & Africa Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 92 Middle East & Africa Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Middle East & Africa Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 94 Middle East & Africa Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 95 South Africa Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 96 South Africa Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 South Africa Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 98 South Africa Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 99 Saudi Arabia Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 100 Saudi Arabia Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Saudi Arabia Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 102 Saudi Arabia Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 103 UAE Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 104 UAE Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 105 UAE Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 106 UAE Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million
  • Table 107 Kuwait Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 108 Kuwait Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 109 Kuwait Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 110 Kuwait Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cardiac biomarkers: Market outlook
  • Fig. 8 Cardiac biomarkers: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Cardiac biomarkers market driver impact
  • Fig. 13 Cardiac biomarkers market restraint impact
  • Fig. 14 Cardiac biomarkers market strategic initiatives analysis
  • Fig. 15 Cardiac biomarkers market: Type movement analysis
  • Fig. 16 Cardiac biomarkers market: Type outlook and key takeaways
  • Fig. 17 Troponin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 CK-MB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Myoglobin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 BNP and NT-proBNP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiac biomarkers market: Application movement analysis
  • Fig. 23 Cardiac biomarkers market: Application outlook and key takeaways
  • Fig. 24 Acute coronary syndrome market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myocardial infarction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Congestive heart failure market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiac biomarkers market: End use movement analysis
  • Fig. 29 Cardiac biomarkers market: End use outlook and key takeaways
  • Fig. 30 Laboratory testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Point of care testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pain management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Vaccine delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Other end use market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiac biomarkers market: Regional movement analysis
  • Fig. 37 Global cardiac biomarkers market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)